Background: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by pathogenic variants in the SACS gene and is characterized by ataxia, peripheral neuropathy, pyramidal impairment and episodic conditions such as epilepsy. Paroxysmal kinesigenic dyskinesia (PKD) had not been previously described in ARSACS.
Introduction
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS, OMIM #270550) is an early-onset progressive disorder that mainly presents with spinocerebellar ataxia, upper motor neuron dysfunction, and distal sensorimotor and peripheral neuropathy (1) . ARSACS is caused by pathogenic variants in SACS (2) . Paroxysmal kinesigenic dyskinesia (PKD, OMIM #128200) is characterized by recurrent and brief attacks of dystonia and choreoathetosis lasting no more than 1 minute, triggered by sudden movements (3) . Mutations in PRRT2 and SCN8A are associated with PKD (4, 5) . We describe here two independent cases bearing SACS mutations presented with ARSACS and PKD, which expands the clinical phenotype associated with SACS mutations to include PKD.
Methods
The study was approved by the ethical review board of Peking Union Medical College Hospital. Both families provided written informed consent for clinical-genetic correlation studies.
Genetic analysis
Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) according to standard protocols. Mutations in PRRT2 were excluded by Sanger sequencing, and WES was then performed on the two patients. Exonic regions were captured and enriched using an Agilent SureSelect Human All Exon 50 Mb kit (Agilent, Santa Clara, CA, USA). The captured fragments were purified and sequenced on a Hiseq2000 platform (Illumina, San Diego, CA, USA) using 90-bp paired-end reads. The sequence was aligned to the human reference genome (UCSC hg19) using a Burrows-Wheeler Aligner (6) . The aligned sequence files were reformatted using SAMtools (7) . Subsequent annotation was performed using SeattleSeq Annotation 138 (http://snp.gs.washington.edu/SeattleSeqAnnotation138/), SIFT (http://sift.jcvi.org/), and PolyPhen2 (http://genetics. bwh.harvard.edu/pph2/). Variant frequencies were initially determined in dbSNP, the 1000 Genomes Project, and the NHLBI Exome Sequencing Project version ESP6500 exome variant server [http://evs.gs.washington.edu/ EVS/ (1 Dec 2013)] to remove common single nucleotide polymorphisms (SNPs). Only nonsynonymous, splicing and frameshift variants with minor allele frequency (MAF) <0.5% or that were absent in population databases were selected for further assessment. De novo mutations suggestive of a dominant disease model or homozygous and compound heterozygous variants of a recessive model were identified and subjected to Sanger sequencing. Genes that may potentially be related to paroxysmal dystonic symptoms were carefully excluded. The WES results of 163 PKD patients without additional symptoms (patients from a previous experiment (8) were also reviewed.
Results

Case reports
Patient 1 is a 14-year-old male. He developed unsteady gait and poor coordination at approximately 2 years old. Weakness and numbness were also reported, and all the symptoms progressively worsened. At the age of eight, he experienced recurrent and brief attacks of dystonia in unilateral or bilateral limbs triggered by sudden movements, stress or anxiety. The attacks lasted less than 10 seconds and were completely relieved by carbamazepine (CBZ) (200 mg/day). He reported no seizure attacks. Upon physical examination, he had jerky ocular pursuits, saccade dysmetria, mild distal weakness, pyramidal signs, cerebellar ataxia and high arch ( Figure 1A) .
Patient 2 is a 12-year-old female. She had strangling steps from 1.5 years on that worsened as ataxia became prominent. Mild learning difficulties were also noticed after she had entered primary school. When she was 10 years old, she began to experience episodes of unilateral or bilateral dystonia, causing instant falls with consciousness reserved. These attacks may be triggered by sudden movements or stress. Each attack lasted approximately 5 seconds and was favorably controlled by low-dose CBZ (100 mg/day). Her parents observed no seizure events. Physical examination showed dysarthria, counting deficits, saccade dysmetria, distal weakness, pyramidal signs, and cerebellar ataxia.
For both patients, routine serum tests, blood lactate concentration, ceruloplasmin, organic acids and amino acids were performed and were all within normal ranges. Neurophysiological examination revealed large-fiber sensorimotor axonal-demyelinating neuropathy. Brain magnetic resonance imaging revealed generalized atrophy, most markedly affecting the cerebellum. Typical cerebellar and pontine changes manifesting as hypointensities in T2-weighted images associated with ARSACS (9) were observed in our patients (see Figure 1B ). For both patients, electroencephalography (EEG) detected no epileptic discharges. Increased amounts of slow waves in the bilateral frontal lobe were detected in Patient 2. Neurophysiological examination showed sensorimotor axonal polyneuropathy for both patients.
Genetic tests for spinocerebellar ataxias 1, 2, 3, 6, 7, 8, 10, 12 and 17, Friedreich ataxia, and dentatorubralpallidoluysian atrophy (DRPLA) were negative, and patients' DNA samples were subsequently subjected to whole-exome sequencing (WES). After the SACS mutations were identified, both patients were treated with energy supplements primarily to treat mitochondrial deficits. During the 4-year follow up, Patient 1 deteriorated slowly 
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in his motor skills, with mild distant limb numbness and weakness. However, other than that, his ataxia was relatively stable, and his PKD was controlled satisfactorily. Patient 2 was lost to follow-up. None of the rare variants with a minor allele frequency less than 0.5% were identified in the known genes associated with PKD. As other paroxysmal dystonic disorders cannot be completely excluded, genes potentially associated with the current symptoms were also carefully examined. These included the genes of ADCY5, ATP1A3, GCH1, KCNMA1, PARK2, MR1, SLC2A1, KCNA1, CACNB4, CACNA1A, CACNB4, SLC1A3, KCNQ2 and SLC1A3. One variant was found in CACNA1A (c.1337T>C) in Patient 2. It was inherited from her mother who had no history of episodic symptoms and showed no signs of ataxia upon physical examination. The CACNA1A variant was thus considered less likely to be the causal gene. All potential pathogenic variants of the two patients are listed in Tables S1 and S2.
The SACS gene (NM_014363.5) was the only gene associated with the existing phenotype in concordance with the symptoms of Patient 1 and Patient 2 and shared by them. Novel compound heterozygous or homozygous variants were revealed when comparing candidate genes and were confirmed by Sanger sequencing in both patients. Patient 1 holds one missense and one frameshift variant in the SACS gene (c.9019C>T, p.P3007S and c.10174_10183del, p.H3392fs) (Figure 2A) . The homozygous variant presented in Patient 2 (c.4127G>A, p.W1376X) ( Figure 2B) should be deleterious and would possibly cause truncation of the SACS protein. In both patients, each mutant allele was inherited from one of his or her unaffected parents. All 3 mutations had not been reported before and were absent in 196 ethnic-matched control chromosomes or in data from the 1000 Genomes Project. They were thus assigned as likely pathogenic.
In searching for additional genes that may have caused the PKD symptoms of our patients, we also reviewed the WES results of patients with pure PKD symptoms for SACS variations. There were 34 patients who carried heterozygous variants out of 163 PKD patients. However, 17 of these variants were documented in public databases with a reported allele frequency of over 0.3%. Three patients carried a pathological PRRT2 mutation simultaneously. No homozygous or compound heterozygous variants in the SACS gene were detected in these patients.
Discussion
ARSACS is a neurodegenerative disease resulting from mutations in SACS. Over 170 mutations with diverse phenotypes have been reported worldwide and are thought to cause loss of function of sacsin (1) . The typical ARSACS phenotype consists of a childhood-onset triad of cerebellar ataxia, peripheral neuropathy, and pyramidal tract signs. Reports describe patients with atypical features in addition to ataxia and peripheral neuropathy, which include delayed 
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onset ataxia, non-ataxic spastic paraplegia, mild pyramidal signs, cognitive decline, and widespread supratentorial abnormalities (10) (11) (12) (13) . Seizures including progressive myoclonus epilepsies were also reported (11, (14) (15) (16) . PKD, however, has never been documented in ARSACS before. Commonly, PKD is simple and pure in phenotype in addition to its association with epilepsy and migraines. Herein, we described 2 unrelated patients bearing mutations in SACS who presented with ARSACS and PKD. These findings may indicate that SACS is highly likely the causal gene of the combined syndrome and should be put to future biological validation.
The SACS gene encodes sacsin, a protein located on the mitochondrial surface. Sacs knockout (Sacs -/-) mice displayed an abnormal gait with progressive motor dysfunction. Clinical features were accompanied by an early onset, progressive loss of cerebellar Purkinje cells followed by spinal motor neuron loss and peripheral nerve dysfunctions highly reminiscent of ARSACS (17) . Remarkable bioenergetic damage in ARSACS cells is indicated by reduced basal, adenosine triphosphate (ATP)-linked and maximal mitochondrial respiration rates and by reduced respiratory chain activities and mitochondrial ATP synthesis (18) . These findings show that defects in mitochondrial dynamics are the underlying pathophysiological basis of ARSACS (19) . Supplementation of mitochondrial energy may thus be the current plan for symptom rescue, and it can be expected that in the near future, gene therapy may possibly be the cure.
In conclusion, we identified mutations in the SACS gene in two independent patients with ARSACS and PKD. Patients with SACS mutations may manifest a PKD phenotype under the background of ARSACS. This is different from PKD patients with mutations in PRRT2 or other mutant genes, such as SCN8A, who show relatively pure paroxysmal dystonic deficits. 
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